Advancing biopharma companies from early innovation to scalable growth.
Early-stage biotech success is rarely limited by science alone. The companies that grow are the ones that align critical forces early and deliberately.
Early-stage biotech success is rarely limited by science alone. The companies that grow are the ones that align critical forces early and deliberately.
It comes from aligning science, strategy, and execution around a single direction. When alignment is intentional, decisions accelerate and growth follows.
"When alignment is missing, even exceptional science stalls."
I collaborate with exceptional teams on three critical vectors to bridge the gap from breakthrough to impact.
I am a biopharma inventor and entrepreneur, bringing together deep foundations in genomics research, intellectual property strategy, and company creation.
I work closely with leadership teams to translate scientific breakthroughs into real-world impact.
My areas of focus are capital formation, business development, and strategic execution.
I do not simply advise and depart; I remain embedded with leadership teams to ensure our strategies are rigorously employed and our shared objectives are fully realized.
Strategic growth requires early deliberation. Reach out to discuss how we can bridge the gap from scientific breakthrough to commercial execution.